Safety, Tolerability, Pharmacokinetics, and Efficacy of Terlipressin Delivered by Continuous Intravenous Infusion in Patients with Cirrhosis and Refractory Ascites

Table 2

Summary of outcomes from treatment per patient.

Parameter	Subjects
	101	102	103	104	105	106
Treatment days (dose, mg/d)	28 (3)	14 (4)	24 (2)	28 (3)	9 (3)	28 (3)
Reason for stopping	NA	Recurrent HE	Leaking hernia	NA	Grade 3 hyponatremia	NA
Spironolactone/furosemide, mg/d
Pretreatment	150/60	200/60	None	100/40	100/20	100/160
Treatment	50/20	200/60	None	100/40	100/20	100/160
LVP interval, days/28-day period
Pretreatment	7	18	7	14	21	21
Treatment	7	29	13	74	63	20
% change in LVP interval	0	70	116	414	215	-5
Total volume of ascites removed/28-day period, L
Pretreatment	45.0	25.8	33.0	19.7	16.5	17.5
Treatment	29.0	0	22.6	0	0	12.1
% change in volume	-36	-100	-32	-100	-100	-31
Change in SCr (mg/dL)	-0.4	0	-1.0	-0.4	-0.4	-0.1

HE: hepatic encephalopathy; NA: not applicable; SCr: serum creatinine.